The sustainability argument is a strong one in favour of tax-based systems — read our commentary pubmed.ncbi.nlm.nih.gov/26369417/

We further map genomic utility evidence from different publicly funded rare disease genomic tests in Australia onto the GUV scale to indicate acceptable #thresholds of #genomic_utility to support prioritization decisions.
Read more here doi.org/10.1016/j.jv...

How the GUV scale can be used to support policy decisions is illustrated through a stylized example.

The scale can be used
by researchers in rare disease genomics to design evaluations that capture the key outcomes of genomics &
by health technology assessment (HTA) bodies to support policy decisions based on standardized and quantifiable evidence of genomic utility.

Using @1OOOminds, we performed a multicriteria decision analysis #MCDA with experts involved in policy, clinical, research, and consumer advocacy leadership to enable the cumulative and preference-based scoring of genomic utility on a 0 to 100 scale.

Our work, published in #ValueinHealth @ISPORJournals, now enables consistency in reporting and benchmarking of different genomic test indications, facilitating evidence-based research and policy decisions.

Testament to the quality of the work we did with Australian Genomics and the hard work of everyone in my Economics of Genomics and Precision Medicine Unit and Australian Genomics teams!

Drinking coffee now from my not so secret Santa gift